Prosecution Insights
Last updated: October 04, 2026
Application No. 18/946,181

COMPOSITIONS COMPRISING ULTRAFINE BUBBLES AND METHODS OF USING THEREOF IN A METHOD OF PRODUCING AND DELIVERING ACTIVE PHARMACEUTICAL INGREDIENTS AND OTHER DISSOLVED SOLUTES

Non-Final OA §103
Filed
Nov 13, 2024
Priority
Nov 16, 2023 — provisional 63/599,695 +1 more
Examiner
GULLEDGE, BRIAN M
Art Unit
Tech Center
Assignee
Hydrosome Ip LLC
OA Round
1 (Non-Final)
56%
Grant Probability
Moderate
1-2
OA Rounds
1y 5m
Est. Remaining
82%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allowance Rate
535 granted / 959 resolved
-4.2% vs TC avg
Strong +26% interview lift
Without
With
+26.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
62 currently pending
Career history
988
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
50.0%
+10.0% vs TC avg
§102
13.2%
-26.8% vs TC avg
§112
21.0%
-19.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 959 resolved cases

Office Action

§103
DETAILED ACTION AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Election/Restrictions Applicant’s election without traverse of Group I (claims 1 and 4-10) and the species of vitamin in the reply filed on 24 August 2026 is acknowledged. Claims 11-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1 and 4-10 are rejected under 35 U.S.C. 103 as being unpatentable over Jahana et al. (US Patent Application Publication 2023/0056021). Jahana et al. discloses methods for generating ultrafine bubbles (abstract). The ultrafine bubbles can be prepared in water (examples & claim 6). The ultrafine bubbles may then be incorporated into numerous applications (paragraph [88]). One such application is food and drink, where the additional ingredients suggested include vitamins (paragraph [92]). Jahana et al. thus discloses compositions comprising the individual elements instantly claimed (water and vitamins present with the ultrafine bubbles) and together these would provide a composition as instantly claimed. However, Jahana et al. is not anticipatory insofar as these combinations must be selected from various lists/locations in the reference. It would have been prima facie obvious, however, to make the combination since each component is taught as being useful in making the compositions of the prior art. Since this modification of the prior art represents nothing more than the predictable use of prior art elements according to their established functions a prima facie case of obviousness exists. See MPEP 2141. Instant claim 1 and dependent claims 4 and 10 recite features of the composition (such as it increasing cell permeability of the vitamin). While Jahana et al. does not teach this feature, it is reasonable to conclude that aqueous ultrafine bubbles would provide for this property in view of the teaching of the instant specification (paragraph [62]). Instant claim 5 further limits the size of the bubbles. Jahana et al. discloses a size which does not read upon the instantly recited range but does overlap (paragraph [22] & claim 9). And in cases involving overlapping ranges, where the instantly claimed ranges “overlap or lie inside ranges disclosed by the prior art”, a prima facie case of obviousness exists. See MPEP 2144.05. Instant claim 6 further limits the concentration of the vitamins. While this concentration is not suggested by Jahana et al., generally differences in concentration and tempera-ture will not support the patentability of subject mat-ter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to dis-cover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). See MPEP 2144.05(II)(A). Instant claim 7 further limits the time the bubbles are stable, and Jahana et al. teaches such a feature (paragraph [50]). Instant claim 8 recites a limitation to the manner in which the bubbles are prepared. Jahana et al. does not teach the specific manner instantly recited in which the bubbles are prepared. However, the patent-ability of a product does not depend on its method of production, and if the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process. See MPEP 2113. Instant claim 9 recites a limitation to the use (oral suitability), and the food and drink application taught by Jahana et al. addresses this limitation. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Gulledge whose telephone number is (571) 270-5756. The examiner can normally be reached Monday - Friday 7am - 4pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at (571) 272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Brian Gulledge/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Nov 13, 2024
Application Filed
Sep 23, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746202
CATIONIC LIPID HAVING DISULFIDE BOND, LIPID MEMBRANE STRUCTURE INCLUDING SAME, NUCLEIC ACID INTRODUCTION AGENT AND PHARMACEUTICAL COMPOSITION CONTAINING ANY ONE OF SAME, METHOD FOR INTRODUCING NUCLEIC ACID INTO CELL OR TARGET CELL, AND METHOD FOR PRODUCING CELLULAR PHARMACEUTICAL
2y 0m to grant Granted Sep 29, 2026
Patent 12714668
Method of Preparing a Gelling Agent, the Gelling Agent Obtained Thereby, and the Use of Said Gelling Agent
2y 2m to grant Granted Aug 25, 2026
Patent 12708600
COSMETIC COMPOSITION COMPRISING AN AMINO SILICONE, A NON-AMINO SILICONE AND A NON-IONIC ASSOCIATIVE POLYMER, AND COSMETIC TREATMENT PROCESS
3y 2m to grant Granted Aug 18, 2026
Patent 12708594
SULFATE FREE PERSONAL CLEANSING COMPOSITION COMPRISING LOW INORGANIC SALT
2y 4m to grant Granted Aug 18, 2026
Patent 12690587
ANIMAL AND INSECT REPELLENT AND METHOD OF ITS USE
2y 9m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
56%
Grant Probability
82%
With Interview (+26.1%)
3y 4m (~1y 5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 959 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month